Skip to content
  • en
  • fr
 
Nicox.com
visible science
Nicox.comNicox.com
  • About Nicox
    • Who we are
    • Our approach
    • Partnerships
    • Leadership team
    • Board of directors
    • Glaucoma Clinical Advisory Board
  • R&D
    • Pipeline
    • Research platform
    • Disease focus areas
      • Glaucoma
      • Conjunctivitis
      • Blepharitis
    • Products / Product candidates
    • Publications
  • Investors
    • Stock information
    • Financial information
      • Balance sheet and P&L
      • Financial calendar
      • Presentation of financial results
    • Annual report
    • Shareholder meetings
    • Fund raising
    • Corporate governance
    • Regulated information
      • Financial information
      • Voting rights
      • Share liquidity agreements
      • Alerts (prospectus)
      • Press releases
      • Alerts (shareholders meetings)
    • FAQs
  • News & media
    • News
    • Press releases
  • Presentations & Events
    • Presentations & webcasts
    • Events
  • Contact
    • Where we are
    • Main subsidiaries
    • Contact us
    • Working with us
  • About Nicox
    • Who we are
    • Our approach
    • Partnerships
    • Leadership team
    • Board of directors
    • Glaucoma Clinical Advisory Board
  • R&D
    • Pipeline
    • Research platform
    • Disease focus areas
      • Glaucoma
      • Conjunctivitis
      • Blepharitis
    • Products / Product candidates
    • Publications
  • Investors
    • Stock information
    • Financial information
      • Balance sheet and P&L
      • Financial calendar
      • Presentation of financial results
    • Annual report
    • Shareholder meetings
    • Fund raising
    • Corporate governance
    • Regulated information
      • Financial information
      • Voting rights
      • Share liquidity agreements
      • Alerts (prospectus)
      • Press releases
      • Alerts (shareholders meetings)
    • FAQs
  • News & media
    • News
    • Press releases
  • Presentations & Events
    • Presentations & webcasts
    • Events
  • Contact
    • Where we are
    • Main subsidiaries
    • Contact us
    • Working with us

Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis

Post navigation

PreviousPrevious post:Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in BlepharitisNextNext post:Nicox’s corporate presentation – update January 29, 2019
Nicox.com

©2019 Nicox, all rights reserved
Last modified: 29/01/2019

  • Contact |
  • About Nicox |
  • Legal notice |
  • Information about cookies |